By: IPP Bureau
Last updated : November 19, 2025 10:14 am
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
Sudeep Pharma Limited has announced the price band for its maiden public offering at Rs. 563-Rs.593 per equity share, marking its debut on the bourses.
The IPO opens for subscription on November 21, 2025, and will close on November 25, 2025, with an anchor book scheduled for November 20, 2025. Investors can bid for a minimum of 25 shares and in multiples of 25 thereafter.
The issue comprises a fresh issue of Rs. 95 crore and an offer-for-sale of up to 13.49 million shares by the promoter and promoter group, targeting a total raise of around Rs. 895 crore. Proceeds from the fresh issue, approximately Rs. 75.8 crore, will be deployed for capital expenditure, primarily to acquire machinery for its Nandesari Facility 1 in Gujarat, along with general corporate purposes.
Sudeep Pharma is a technology-driven manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. Its proprietary technologies support processes including encapsulation, spray drying, granulation, trituration, liposomal preparations, and blending, driving innovation in manufacturing.
The company has a strong global footprint, serving over 100 countries across the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
It is among the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and food and beverage sectors, boasting a combined annual manufacturing capacity of 72,246 metric tons as of June 30, 2025. Notably, one of its facilities is USFDA-approved for mineral-based ingredient production.
ICICI Securities Limited and IIFL Capital Services Ltd are acting as book-running lead managers, while MUFG Intime India Private Limited is the registrar for the offer.